Discussion on the Mechanism of Poria-Alismatis Rhizoma Medicinal Pair for the Treatment of Chronic Glomerulonephritis Based on Network Pharmacology
Objective To explore the material basis and mechanism of Poria-Alismatis Rhizoma medicinal pair for the treatment of chronic glomerulonephritis(CGN)based on network pharmacology approach.Methods The active components of Poria-Alismatis Rhizoma medicinal pair were obtained through TCMSP database and the active component targets were predicted on PharmMapper platform;the active component-target network diagram was constructed through Cytoscape 3.8.2 software;targets related to CGN were obtained from GeneCards,OMIM database;the Venny 2.1 online drawing tool platform was used to build Wayne diagrams,to obtain the intersecting targets;the intersecting targets were imported into STRING database to construct PPI network,and the key targets were screened by Cytoscape 3.8.2 software and CytoNCA plug-in;the key targets were enriched for GO function and KEGG pathway with the help of DAVID database.Results A total of 25 active components of Poria-Alismatis Rhizoma medicinal pair,89 targets,1 240 CGN-related targets,31 intersectional targets and 15 key targets were obtained.The main active components were poriaxin acid A,zeolol C,poriaxin acid B,dehydroporiaxin acid,etc.Key targets included ALB,EGFR,SRC,CASP3,etc.Key targets GO enrichment analysis yielded 106 relevant entries,biological processes were mainly enriched in lipids and atherosclerosis,endocrine resistance,lung cancer proteoglycans,etc.;the KEGG pathway obtained 81 signaling pathways,mainly involving vascular endothelial growth factor(VEGF)signaling pathway,tumor necrosis factor(TNF)signaling pathway,interleukin-17(IL-17)signaling pathway,and so on.Conclusion The Poria-Alismatis Rhizoma medicinal pair may exert pharmacological effects such as anti-inflammatory,antioxidant,regulation of apoptosis,inhibition of glomerular mesangial cell proliferation,and delaying the progression of renal fibrosis by regulating the VEGF signaling pathway,TNF signaling pathway,and IL-17 signaling pathway through the target such as ALB,EGFR,and SRC to treat CGN.
国家科技期刊平台
NSTL
万方数据
维普
